Goldman Sachs Amends Milestone Pharma Stake (SC 13G/A)
Ticker: MIST · Form: SC 13G/A · Filed: Feb 9, 2024 · CIK: 1408443
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, beneficial-ownership
TL;DR
**Goldman Sachs just updated its stake in Milestone Pharma; keep an eye on institutional confidence.**
AI Summary
Goldman Sachs Group Inc. filed an amended Schedule 13G/A on February 9, 2024, indicating a change in their beneficial ownership of Milestone Pharmaceuticals Inc. common shares as of December 29, 2023. This filing, an amendment to a previous disclosure, signals that Goldman Sachs continues to hold a significant, though potentially adjusted, stake in Milestone Pharmaceuticals. For investors, this matters because large institutional holdings like Goldman Sachs's can influence stock stability and market perception, and any changes could signal shifts in institutional confidence in the company's future.
Why It Matters
This filing shows that a major financial institution, Goldman Sachs, has updated its ownership position in Milestone Pharmaceuticals, which can impact investor sentiment and the stock's liquidity.
Risk Assessment
Risk Level: low — An amended 13G filing from a major institution like Goldman Sachs is a routine disclosure and doesn't inherently signal high risk, but rather transparency in ownership changes.
Analyst Insight
An investor should monitor future 13G/A filings from Goldman Sachs to track any significant increases or decreases in their stake, as this could signal a change in their long-term outlook on Milestone Pharmaceuticals Inc.
Key Players & Entities
- Goldman Sachs Group Inc. (company) — the entity filing the SC 13G/A, reporting beneficial ownership
- Milestone Pharmaceuticals Inc. (company) — the issuer whose common shares are being reported
- December 29, 2023 (date) — the date of the event requiring the filing of the statement
- February 9, 2024 (date) — the date the SC 13G/A was filed
- 59935V107 (other) — the CUSIP number for Milestone Pharmaceuticals Inc. Common Shares
Forward-Looking Statements
- Goldman Sachs will maintain a significant institutional stake in Milestone Pharmaceuticals Inc. for the foreseeable future. (Goldman Sachs Group Inc.) — medium confidence, target: December 29, 2024
FAQ
What type of filing is this document and what does it indicate?
This document is an SC 13G/A, which is an amendment to a Schedule 13G. It indicates that Goldman Sachs Group Inc. has updated its beneficial ownership report regarding the common shares of Milestone Pharmaceuticals Inc. as of December 29, 2023.
Who is the 'subject company' in this filing?
The subject company, whose securities are being reported, is Milestone Pharmaceuticals Inc., with a Central Index Key (CIK) of 0001408443 and a business address at 1111 Boul. Dr.-Frederik-Philips, Ste 420, Montreal, A8 H4M 2X6.
Who is the 'filed by' entity in this document?
The entity that filed this report is Goldman Sachs Group Inc., with a Central Index Key (CIK) of 0000886982 and a business address at 200 West Street, New York, NY 10282.
What is the CUSIP number for the class of securities mentioned?
The CUSIP number for the Common Shares of Milestone Pharmaceuticals Inc. is 59935V107, as stated on the cover page of the filing.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the 'X' in the appropriate box on the cover page.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 9, 2024 regarding Milestone Pharmaceuticals Inc. (MIST).